Dergiler / art / 2020 / Cilt: 35 - Sayı: 3

Retrospective Analysis of the Factors Affecting Growth Parameters in Turkish Children With Systemic Lupus Erythematosus

Dergi
art
Sayfa
357–365
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The patients treated with at least 10 g of cumulative dose of corticosteroids had lower mean height z-score.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to investigate the growth parameters in Turkish children with systemic lupus erythematosus (SLE) and to compare these growth parameters according to the presence or absence of cyclophosphamide, rituximab treatment, cumulative corticosteroid dose, proliferative nephritis, and the last visit disease activity and damage index.
📊
Temel Bulgular & Veri:Patients and methods: Medical data, growth parameters including z-scores for weight, height, and body mass index and parent-adjusted height z-scores of 45 juvenile SLE (jSLE) patients (5 males, 40 females; mean age 12.3±3.2 years; range 7.1 to 18 years) were retrospectively evaluated.
💡
Sonuç & Katkı:The patients treated with at least 10 g of cumulative dose of corticosteroids had lower mean height z-score.
🔬Tür:Araştırma Makalesi
📍Kapsam:2000 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: This study aims to investigate the growth parameters in Turkish children with systemic lupus erythematosus (SLE) and to compare these growth parameters according to the presence or absence of cyclophosphamide, rituximab treatment, cumulative corticosteroid dose, proliferative nephritis, and the last visit disease activity and damage index. Patients and methods: Medical data, growth parameters including z-scores for weight, height, and body mass index and parent-adjusted height z-scores of 45 juvenile SLE (jSLE) patients (5 males, 40 females; mean age 12.3±3.2 years; range 7.1 to 18 years) were retrospectively evaluated. Growth parameters were calculated by anthropometric references in Turkish children. The disease activity was assessed by the SLE Disease Activity Index 2000 (SLEDAI-2K). The disease outcome was measured by the Pediatric version of Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Results: The median diagnostic delay was two months (range, 0-36 months). The median follow-up duration was 3.21 years (range, 0.63-9.48 years). Mean height z-score was significantly lower at last visit than at the time of diagnosis. The growth parameters did not differ according to age at disease onset, diagnostic delay, presence of proliferative nephritis, having cyclophosphamide and rituximab treatment and the last visit (SLEDAI-2K) scores. The median duration of corticosteroid treatment was 3.2 years (range, 0.6-9.4 years) and the median cumulative corticosteroid dosage was 13.9 g (range, 1.9-58 g) of methylprednisolone. The mean height z-score at last visit was significantly lower in those who received at least 10 g of cumulative dose of corticosteroid. The last visit mean parent-adjusted height z-scores did not differ significantly regarding the cumulative corticosteroid dose. Conclusion: The last visit height and parent-adjusted height z-scores of jSLE patients were significantly lower. The patients treated with at least 10 g of cumulative dose of corticosteroids had lower mean height z-score.

🔖

Bu Makaleye Atıf Yap

BALCI, S., EKİNCİ, R. M. K., MELEK, E., BAYAZIT, A. K., DOĞRUEL, D., ALTINTAŞ, D. U., YILMAZ, M. (2020). Retrospective Analysis of the Factors Affecting Growth Parameters in Turkish Children With Systemic Lupus Erythematosus. art, Cilt: 35 - Sayı: 3, 357–365. https://ajindex.com/articles/142819

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Klein-Gitelman M, Lane JC. Systemic lupus erythematosus. In: Petty R, Laxer R, Lindsley C, Wedderburn L, editors. Textbook of Pediatric Rheumatology. 7th ed. Philadelphia: Saunders; 2010. p. 285-317.
  2. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 2009;36:2539-46.
  3. Balci S, Ekinci RMK, Bayazit AK, Melek E, Dogruel D, Altintas DU, et al. Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey. Clin Rheumatol 2019;38:1459-68.
  4. Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:1152-9.
  5. Ravelli A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:568-73.
  6. Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006;15:515-20. Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006;54:2989-96.
  7. Hiraki LT, Hamilton J, Silverman ED. Measuring permanent damage in pediatric systemic lupus erythematosus. Lupus 2007;16:657-62. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
  8. Neyzi O, Günöz H, Furman A, Bundak R, Gökçay G, Darendeliler F, et al. Türk çocuklarında vücut a¤ırlı¤ı, boy uzunlu¤u, ba çevresi ve vücut kitle indeksi referans de¤erleri. Çocuk Sa¤lı¤ı ve Hastalıkları Dergisi 2008;51:1-14.
  9. Sahin S, Adrovic A, Barut K, Canpolat N, Ozluk Y, Kilicaslan I, et al. Juvenile systemic lupus erythematosus in Turkey: demographic, clinical and laboratory features with disease activity and outcome. Lupus 2018;27:514-9.
  10. Gulay CB, Dans LF. Clinical presentations and outcomes of Filipino juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J 2011;9:7. Salah S,